← Back to Patent Explorer
US5419900A Expired / Lapsed US ⏱️ 0.0 years remaining

Immunologic enhancement with intermittent interleukin-2 therapy

Assignee: United States Department of Health and Human Services
•
Filing: 1993-05-19
•
Granted: 1995-05-30
•
Expires: 2013-05-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for activating a mammalian immune system entails a series of continuous IL-2 infusions that are effected intermittently over an extended period. For example, IL-2 can be administered continuously for a period that is on the order of 5 days in length, and successive infusions of this nature can be separated by a period of at least 4 weeks. Sustained beneficial effects, including elevated CD4 cell counts, restoration of lymphocyte function and an increase in the number of IL-2 receptors, are achieved with such intermittent IL-2 therapy, which can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha.

Inventors

  • 👤 H. Clifford Lane
  • 👤 Joseph A. Kovacs

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 06:38
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2013; A61P; A61P31/00; A61P31/12; A61P37/00; A61P37/02; A61P37/04

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 84 words
A method for activating the immune system of a patient, comprising the step of administering an amount of IL-2 to said patient that is sufficient to increase the level of helper/inducer T-cell function in said patient, wherein: (A) said IL-2 is administered in a series of infusions effected intermittently, (B) each of said infusions is continuous over a period of time of from 1 day to 2 weeks, and (C) successive infusions are separated by a period of time of at least 4 weeks.
Claim 2
Independent Claim 84 words
A method for activating the immune system of a patient, comprising the step of administering an amount of IL-2 to said patient that is sufficient to increase the level of helper/inducer T-cell function in said patient, wherein: (A) said IL-2 is administered in a series of infusions effected intermittently, (B) each of said infusions is continuous over a period of time of from 1 day to 2 weeks, and (C) successive infusions are separated by a period of time of at least 4 weeks.
Claim 3
Dependent Claim 19 words
A method as claimed in claim 1, wherein said amount is sufficient to increase CD4 count in said patient.
Claim 4
Dependent Claim 23 words
A method as claimed in claim 1, wherein each of said infusions comprises a dosage of IL-2 of from 1.8 to 24 MU/day.
Claim 5
Dependent Claim 24 words
A method as claimed in claim 3, wherein said period of time of each of said infusions is on the order of 5 days.
Claim 6
Dependent Claim 23 words
A method as claimed in claim 1, further comprising administering zidovudine to said patient prior to or concomitantly with said administering of IL-2.

References Cited (Backward Citations)

US4908433A Cited
US4866157A Cited
EP0343480A1 Cited
EP0426521A1 Cited
US5026687A Cited
EP0452598A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-05-29 1998-11-28 1999-05-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-05-29 2002-11-28 2003-05-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-05-29 2006-11-28 2007-05-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag